Mitoxantrone-cyclophosphamide-fluorouracil-combination chemotherapy in metastatic breast cancer. 3-Year-follow-up.
Büyükünal
E
E
Department of Internal Medicine, Section of Medical Oncology, Cerrahpaşa Medical Faculty, Istanbul, Turkey.
Derman
U
U
Serdengeçti
S
S
Berkarda
B
B
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003520:Cyclophosphamide / Q000493:pharmacokinetics; D005260:Female; D005472:Fluorouracil / Q000493:pharmacokinetics; D005500:Follow-Up Studies; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D008942:Mitoxantrone / Q000493:pharmacokinetics; D013997:Time Factors
D003520:Cyclophosphamide; D008942:Mitoxantrone; D005472:Fluorouracil